Eritropoetinterápia

Eritropoetinterapia refers to the therapeutic use of erythropoietin, a hormone produced primarily by the kidneys. Erythropoietin stimulates the bone marrow to produce red blood cells. This therapy is most commonly used to treat anemia, a condition characterized by a deficiency of red blood cells.

The main indication for erythropoietin therapy is anemia associated with chronic kidney disease (CKD). In individuals with CKD, the kidneys may not produce enough erythropoietin, leading to reduced red blood cell production. Erythropoietin therapy can help normalize hemoglobin levels and alleviate symptoms of anemia such as fatigue and weakness in these patients.

Another significant use of erythropoietin is in patients undergoing chemotherapy. Certain chemotherapy drugs can suppress bone marrow function, resulting in anemia. Erythropoietin therapy can help counteract this effect, improving hemoglobin levels and reducing the need for blood transfusions. It is also used in some patients before major surgeries to increase red blood cell mass, potentially reducing the risk of transfusion requirements during and after the procedure.

Erythropoietin is typically administered via subcutaneous injection or intravenously. The dosage and frequency of administration are determined by the patient's medical condition, hemoglobin levels, and response to treatment. Monitoring of hemoglobin, hematocrit, and iron levels is crucial during therapy to ensure effectiveness and avoid complications such as hypertension or thrombosis.